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SUMMARY
Objectives—To determine (1) gender-related differences in antiretroviral therapy (ART) 
outcomes, and (2) gender-specific characteristics associated with attrition.
Methods—This was a retrospective patient record review of 3919 HIV-infected patients aged ≥15 
years who initiated ART between 2007 and 2009 in 40 randomly selected ART facilities 
countrywide.
Results—Compared to females, males had more documented active tuberculosis (12% vs. 9%; p 
< 0.02) and a lower median CD4 cell count (117 cells/μl vs. 143 cells/μl; p < 0.001) at ART 
initiation. Males had a higher risk of attrition (adjusted hazard ratio (AHR) 1.28, 95% confidence 
interval (CI) 1.10–1.49) and mortality (AHR 1.56, 95% CI 1.10–2.20). Factors associated with 
attrition for both sexes were lower baseline weight (<45 kg and 45–60 kg vs. >60 kg), initiating 
ART at an urban health facility, and care at central/provincial or district/mission hospitals vs. 
primary healthcare facilities.
Conclusions—Our findings show that males presented late for ART initiation compared to 
females. Similar to other studies, males had higher patient attrition and mortality compared to 
females and this may be attributed in part to late presentation for HIV treatment and care. These 
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observations highlight the need to encourage early HIV testing and enrolment into HIV treatment 
and care, and eventually patient retention on ART, particularly amongst men.
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1. Introduction
With only 12% of the world’s population, Sub-Saharan Africa has 68% of the world’s 
burden of HIV/AIDS cases.1 Zimbabwe, a country in southern Africa, is also badly affected 
by the HIV/AIDS epidemic, with recent statistics showing an HIV prevalence of 15% in the 
15–49 years age group according to the 2010–2011 Zimbabwe Demographic and Health 
Survey.2
Since the national antiretroviral treatment (ART) programme was initiated in 2004, there has 
been a continuous increase in the cohort of HIV-infected individuals accessing this life-
saving intervention in Zimbabwe. The number of health facilities offering ART services 
increased from 7 in 2004 to 960 by December 2012,3 and those receiving ART increased 
from 24 500 people in 2005 to 531 136 by the end of 2012.3 In terms of adult ART 
coverage, the country reached universal access levels of 85% in 2012, but with changing 
global guidelines, which recommended earlier ART initiation, the coverage dropped to 53% 
in December 2013.4
Despite this continued scale-up in numbers of HIV-infected patients receiving ART, a 
growing concern in most ART programmes is patient retention in care, which is critical for 
the success of such programmes. A meta-analysis of 32 ART programs in Africa, excluding 
Zimbabwe, showed that retention was 60%, with loss to follow-up being the major cause of 
attrition, followed by death.5 Partly associated with attrition from HIV treatment and care is 
male gender,6–11 and this has been attributed in part to advanced HIV disease at the time of 
ART initiation7,12 and poor treatment adherence among males.11,13 Despite knowing that 
attrition is higher among males, little is known about differences in the immunological 
response to ART between males and females in the routine ART programme setting. 
Furthermore, few studies have assessed the factors specific to males and females that 
influence attrition from ART. Identifying these gender-specific attrition-associated factors is 
critical for determining priority areas for improving patient retention for each sex.
In Zimbabwe, a review of the national ART programme revealed that patient retention rates 
at 36 months was 64.4% and that male gender increased the risk of attrition.14 Using this 
dataset we conducted an extended data analysis aimed at determining: (1) gender-related 
differences in ART outcomes, primarily attrition from treatment, mortality, loss to follow-up, 
and immunological failure, and (2) gender-specific characteristics associated with attrition.
2. Methods
2.1. Study design
We conducted a retrospective cohort study using routinely collected ART programme data.
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2.2. Setting: general and site-specific
2.2.1. Clinical procedures in the Zimbabwe National ART Programme—ART 
eligibility between 2007 and 2009 was based on national guidelines15 adapted from the 
World Health Organization (WHO):16 ART was initiated in patients with a documented 
HIV-positive test who were classified with WHO clinical stage 3 disease and a CD4+ cell 
count <350/μl, or WHO clinical stage 4 disease, or who had a CD4+ cell count <200/μl 
irrespective of the WHO staging. Although not mandatory, other recommended psychosocial 
criteria for evaluating ART eligibility, as they are considered a measure of patient reliability 
on treatment, were the following: (1) compliance with co-trimoxazole prophylaxis using pill 
counts or keeping appointments, as this will indicate the likelihood of adherence to ART; (2) 
completion of prescribed counselling session(s); (3) availability of a treatment partner and/or 
disclosure to that treatment partner; and (4) ease of follow-up of the patient. Co-trimoxazole 
was commenced at least 2 weeks before ART initiation among adult patients who were 
either in WHO clinical stage 2 or higher, or who had a CD4 cell count <200/μl; this would 
be continued indefinitely or until the CD4 count was >200/μl for >6 months.
Women were checked for pregnancy prior to ART initiation as it was deemed preferable to 
commence ART after the first trimester so as to minimize the risk of teratogenesis.16 The 
recommended first-line ART regimen included two nucleoside reverse transcriptase 
inhibitors (NRTIs), namely stavudine and lamivudine, and one non-nucleoside reverse 
transcriptase inhibitor (NNRTI), namely nevirapine. Zidovudine could replace stavudine in 
the event of drug toxicity, while efavirenz could replace nevirapine in the event of an adverse 
reaction, during pregnancy, or if a patient was commenced on tuberculosis (TB) treatment.
2.2.2. Follow-up in the Zimbabwe National ART Programme—Patients are seen 
every 2 weeks during the first month of ART initiation, then every month for the following 3 
months, and are reviewed every 3 months after the first 4 months. Patients can also visit the 
clinic immediately if they experience any side effects. Recommended clinical and laboratory 
monitoring indices include the patient’s weight, WHO clinical stage, development of 
opportunistic infections (OIs), complete blood count (CBC), serum alanine transaminase 
(ALT), serum creatinine, and when available CD4+ cell counts. (Note: CD4 testing was not 
widely available between 2007 and 2009. By end of 2009, 68 CD4 machines were in 59 
facilities located in 47 out of the country’s 62 districts.17) Routine clinical monitoring is 
recommended every 3 months, CBC and CD4 cell counts should be conducted every 6 
months, and ALT and creatinine should be measured every 12 months. Patient demographic, 
clinical, and laboratory information and visit dates are recorded in the Ministry of Health 
and Child Care (MOHCC) medical records maintained at the health facility.
2.2.3. Treatment outcome measures—ART outcomes during data abstraction were 
categorized as alive and retained on therapy, died, stopped treatment, transferred out, 
defaulted, loss-to-follow-up (LTFU), and other. LTFU was defined as patient absenteeism 
from a healthcare facility for >90 days after the last scheduled appointment with the 
healthcare provider or pharmacy, whilst defaulters were those who had not come back to the 
clinic for <90 days from the last scheduled appointment. The LTFU date was recorded as the 
date of the most recent visit or one day after ART initiation if patients only attended the 
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initiation visit. In this analysis, our primary outcomes of interest were clinical ART 
outcomes and immunological failure. Clinical outcomes comprised all-cause mortality, 
LTFU, and attrition. Attrition referred to patients who were documented as having stopped 
ART, died, or who were LTFU. Immunological failure was defined in line with WHO 
200616 and the Zimbabwe National ART guidelines15 as (1) a decline in CD4+ cell count 
after ≥6 months on therapy, (2) a fall to pre-therapy CD4 count/percentage, or (3) a CD4 
count ≤100 cells/μl after at least 6 months on therapy. Overall immunological failure was 
then determined as having been classified with immunological failure by any of the three 
criteria stated above.
2.2.4. Study sites—The study was conducted in 40 of 70 health facilities that were 
providing ART services to ≥50 HIV-infected patients for ≥6 months by May 31, 2008, for 
the purposes of logistical and financial feasibility. All provinces countrywide were 
represented in the sample whereby sites were selected randomly with the probability of 
selection being proportional to the number of adult patients who had received ART at each 
site, by May 31, 2008.
2.3. Study participants
Patients were included in the study if they were HIV-infected and ≥15 years old and had 
initiated ART between January 1, 2007 and December 31, 2009. Transfer-in patients were 
excluded from the sampling frame in order to avoid double-counting, as they may have been 
abstracted as transfer-out at another selected study site. A minimum of 3842 patients were 
required for the study, assuming a design effect of 2, 50% of adult patients were retained on 
ART at 12 months after ART initiation, a 95% confidence interval of ±2.5%, and 20% of 
charts were missing. Patient charts were selected randomly at each site using an R program.
2.4. Data variables, source of data, and data collection
Data variables included demographic data such as sex and age at enrolment into HIV care. 
Clinical information abstracted included WHO stage, weight, co-trimoxazole use, and CD4 
count prior to ART initiation. Follow-up visit information included weight, haemoglobin, 
CD4 count, clinical stage, co-trimoxazole prescription, ART regimen, and the final patient 
outcome. Selected patient files were retrieved by ART clinic staff who were responsible for 
retrieving selected patient files, whilst missing ones were replaced by the next eligible 
patient record on the randomly ordered list. Trained health workers were responsible for 
abstracting information from patient files into paper-based questionnaires, which were 
eventually entered into an MS Access database and scanned separately into a TeleForm 
database. Differences in the two databases were identified using the SAS %COMPARWS 
Macro.18
2.5. Statistical analysis
Data management was done using SAS 9.2 (SAS Institute Inc., Cary, NC, USA), whilst all 
statistical analyses were performed using Stata/IC 12.1 (StataCorp, 2011, Stata Statistical 
Software: Release 12.1; StataCorp LP, College Station, TX, USA). Data were weighted and 
the analysis accounted for the complex design of the survey using the ‘svy’ prefix command 
in Stata. Domain analyses were performed using the ‘subpop()’ option.
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Missing data were assumed ‘missing at random’ (MAR)19 and were multiple imputed by 
chained equations using the ‘mi impute chained’ procedure in Stata. Twenty imputed 
datasets were created and estimates were combined according to Rubin’s rules19 using the 
‘mi estimate’ procedure. The imputation model included the Nelson–Aelen estimate of 
cumulative hazard,20 baseline demographic and clinical variables, and the event indicator. 
Time-to-event data were complete for all individuals. Twenty-five patients were LTFU after 
their first clinic visit and were assigned one day of person-time.
Gender differences in baseline clinical and demographic characteristics were analysed using 
linear and logistic regression models. These analyses were limited to the first imputed 
dataset. Cox proportional hazards models were used to compare differences in ART 
outcomes (mortality, LTFU, and attrition) and immunological ART outcomes by gender, and 
also to identify gender-specific factors associated with attrition. Multivariable adjusted 
hazard ratios (HRs), their 95% confidence intervals (CI), and p-values were calculated whilst 
adjusting for the potential confounding effects of age, baseline weight, baseline CD4 count, 
baseline WHO staging, prior/current TB, anaemia, size and location of OI/ART clinic, and 
level of health facility. Incidence rates were also calculated for all clinical ART outcomes 
and immunological failure, with the incidence rate being defined as the number of new cases 
attaining each outcome in the patient population per 100 person-years (PY) at risk.
For time-to-event analyses, patients who transferred to another clinic were censored at the 
date of transfer. However, for estimating the various immunological ART outcome 
proportions, the analysis was restricted to those patients with a baseline CD4 count and at 
least one CD4 count result 6 months after ART initiation. Baseline CD4 count was defined 
as the value on the date closest to ART start date but not more than 182 days prior to that 
date or more than 1 day after that date.
2.6. Ethics and approval
The study protocol was approved by the Medical Research Council of Zimbabwe (MRCZ) 
and the Institutional Review Board (IRB) of the United States Centers for Disease Control 
and Prevention prior to data collection. The Union Ethics Advisory Group also reviewed and 
approved this extended analysis protocol.
3. Results
3.1. Baseline demographic, clinical, and immunological characteristics
Data were abstracted from 3919 medical charts of patients eligible for ART. The level of 
missing baseline patient data in these charts varied from <1% (n = 12) for sex, 5% (n = 186) 
for age, 16% (n = 630) for WHO stage, 27% (n = 1049) for body weight, 43% (n = 1688) for 
current active TB, and 53% (n = 2085) for CD4 cell count to 77% (n = 3031) for 
haemoglobin levels. Original and imputed datasets are reported in Table 1, for overall and 
gender-specific baseline demographic and clinical characteristics. The results of the 
weighted imputed data are reported below.
At enrolment into HIV treatment, men were older (39 (interquartile range (IQR) 34–48) vs. 
36 (IQR 31–44) years; p < 0.001), had higher median baseline weight (57 (IQR 47–60) vs. 
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54 (IQR 47–60) kg; p < 0.001), and were more likely to have documented current active TB 
disease (12% vs. 9%; p = 0.02) and documented prior TB disease (13% vs. 9%; p = 0.005). 
Although no gender differences were noted for the period between enrolment into HIV care 
and ART initiation, men were retained on treatment for fewer months when compared to 
women (156 (IQR 6–26) months vs. 17 (IQR 9–28) months; p = 0.018). Similarly the 
median baseline CD4 cell count among males was lower when compared to females (104 
cells/μl (IQR 48–183) vs. 127 cells/μl (IQR 105–181); p < 0.001) and a greater proportion of 
men compared to women had a baseline CD4 count <50 cells/μl (27% vs. 20%, p < 0.001). 
The prevalence of anaemia was high at 79% of the 23% with recorded baseline haemoglobin 
levels, and anaemia prevalence was higher among men than women (81% vs. 78%; p = 
0.023).
3.2. Comparison of patient outcomes by gender
Table 2 shows comparisons of clinical and immunological ART outcomes by gender. Males 
had a higher incidence of attrition (24.0 vs. 19.3 cases/100 PY; p < 0.003), a higher 
incidence of mortality (4.7 vs. 2.9 deaths/100 PY; p = 0.003), and a higher LTFU (4.7 vs. 2.9 
cases/100 PY; p = 0.027). Males continued to have a higher risk of attrition (adjusted hazard 
ratio (AHR) 1.24, 95% confidence interval (CI) 1.08–1.43; p = 0.004), mortality (AHR 1.56, 
95% CI 1.10–2.20; p = 0.014), and LTFU (AHR 1.23, 95% CI 1.05–1.44; p = 0.012) after 
adjusting for potential confounding. The overall incidence of clinical immunological failure 
was low in this cohort at 0.3 cases/100 PY and there were no significant differences when 
stratified by gender (AHR 1.24, 95% CI 0.25–6.18; p = 0.786) after adjusting for potential 
confounders.
3.3. Gender-related differences associated with attrition
Table 3 shows gender-specific factors associated with attrition. For males, those with 
baseline weights of 45–60 kg (AHR 1.37, 95% CI 1.06–1.76; p = 0.017) and <45 kg (AHR 
1.82, 95% CI 1.18–2.81; p = 0.009) were at increased risk of attrition when compared to 
those with baseline weights ≥60 kg. Among females, only those with baseline weight <45 kg 
(AHR 1.92, 95% CI 1.36–2.73; p = 0.001) were at increased risk of attrition compared to 
those ≥60 kg. There was a higher risk of attrition among males with WHO stage 4 compared 
to those with WHO stage 1 or 2 (AHR 1.87, 95% CI 1.28–2.73; p = 0.003), whilst no 
differences were noted among females. Accessing treatment from urban areas in comparison 
to rural areas was associated with a higher risk of attrition from care for both males (AHR 
2.48, 95% CI 1.06–5.81; p = 0.0037) and females (AHR 3.12, 95% CI 1.29–7.51; p = 
0.013).
The baseline CD4 count, current active TB, and prior TB infection were not significant risk 
factors for attrition in either males or females after adjusting for confounding. However, 
attrition was higher for males accessing ART from district/mission hospitals (AHR 4.47, 
95% CI 1.36–14.67; p = 0.015) or central/provincial hospitals (AHR 3.52, 95% CI 1.12–
11.11; p = 0.033) when compared to those accessing treatment from primary healthcare 
facilities. A similar trend was observed for females receiving treatment from district/mission 
hospitals (AHR 7.37, 95% CI 2.32–23.36; p = 0.001) and central/provincial hospitals (AHR 
4.74, 95% CI 1.55–14.53; p = 0.008).
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4. Discussion
This study highlights the differences in patient characteristics as well as treatment outcomes 
between males and females in a cohort of HIV-infected patients on ART in the Zimbabwe 
National ART Programme. In this study we observed that males had poorer clinical status 
prior to initiating ART with regards to current and previous TB illness when compared to 
females. Among the few patients who had haemoglobin measurements taken, anaemia was 
more prevalent among males than females, and anaemia has been shown to be a strong risk 
factor for disease progression and death independent of CD4 count and viral load.21,22 
Males also had lower CD4+ cell counts upon initiating ART when compared to females. 
These observations indicate that males generally present late for HIV treatment and care 
when compared to their female counterparts. This is similar to findings of other studies in 
both resource-limited settings7,10,23 and well-resourced settings,24–26 which have shown that 
males tend to have more advanced HIV disease upon initiation of ART. As shown in other 
studies, such differences in late ART initiation between males and females can be attributed 
in part to clinic-level factors such as the presence of prevention of mother-to-child 
transmission of HIV (PMTCT) services at ART sites27,28 and patient-level factors such as 
pregnancy and entry into care through antenatal care (ANC) or PMTCT rather than through 
voluntary counselling and testing (VCT).27 This may also be attributed to a notion of 
masculinity that portrays men as resilient and disease-free and hence contradicts expected 
health-seeking behaviours such as attending regular hospital visits, as reported in a local 
study among rural men.29
Similar to findings from other studies,12,13,30 males had higher mortality and attrition from 
ART care in comparison to females. In our study, mortality was defined as that which had 
been documented in the ART registers and patient files upon abstraction of data. Since no 
efforts were made to follow-up these patients, it is highly likely that there may have been 
more deaths among those who were defined as LTFU in the attrition group, as was reported 
in one unpublished study in Zimbabwe (Chigu 2011) and in other studies from ART 
programmes in resource-limited settings.31 Among males, factors that were associated with 
attrition were lower baseline weight, advanced WHO stage, and accessing treatment from 
urban areas. A study done within the South African ART programme also showed higher 
mortality among males and also attributed this in part to more advanced disease at the time 
ART initiation and differences in response to treatment.7
Similar to males, attrition among females was also associated with lower baseline weight. 
Low weight is a common problem among HIV-infected patients even in the era of ART32 
and has also been shown to be a strong independent predictor of mortality.33 Poor nutritional 
status in HIV-infected patients leads to low immunity, which predisposes these patients to 
many severe OIs, particularly TB. TB is highly prevalent in Sub-Saharan Africa and is not 
easily detected clinically; it is therefore likely to manifest in the early stages of immune 
reconstitution syndrome. Such TB is better detected using more sensitive techniques such as 
the Gene Xpert MTB/RIF assay,34 which until recently was not available in Zimbabwe, 
compared to the conventional acid-fast bacilli smear microscopy. This could partly explain 
why only 12% of patients in this study had active TB at baseline in a setting with high 
HIV/TB co-infection.
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There are two possible reasons for the higher risk of attrition among those accessing 
treatment from urban areas and higher level health facilities. Firstly, this may be explained 
by patients from rural areas or lower level health facilities initiating ART in urban or higher 
level health facilities where there was more chance of finding doctors; these doctors initiated 
ART and the patients then unofficially self-transferred out to rural clinics and lower level 
facilities as ART decentralization expanded. These patients may therefore have been 
misclassified as LTFU. In Zimbabwe, ART initiations were officially done only by medical 
doctors until recently; however nurses who predominantly run rural and lower level health 
facilities have since been empowered to start ART. In Uganda35 and Malawi,36 a 
considerable proportion of these LFTU patients were receiving ART at another facility upon 
tracing them. Secondly, higher proportions of patients with advanced disease may have 
attended these urban and higher level facilities for treatment and eventually ART initiation, 
as they are generally perceived to offer better health services, whilst more stable patients 
may have attended primary care clinics. Such patients with advanced disease are more likely 
to die and may have been masked as LFTU patients. In a systematic review of studies 
tracing ART patients lost to follow-up in resource-limited settings, mortality was shown to 
range from 20% to as high as 60%.31
In contrast to previous studies,37 the baseline CD4 cell count was not associated with 
attrition for both males and females. This could be explained in part by the amount of 
missing baseline CD4 count data, which exceeded 50% for the abstracted patient records, 
although this missing information was variable among sampled patient records and did not 
constitute any specific subgroup of patients. Our study did not assess self-reported ART 
interruptions or adherence, which may be linked to ART attrition. In a Cameroonian study 
by Marcellin et al.,38 pharmacy stock shortages, binge drinking, and the number of self-
reported slimming symptoms were associated with ART interruptions, and food supply 
programs were suggested as interventions to limit these ART interruptions.
Other study limitations include missing data on haemoglobin measurements, and given that 
nearly three-quarters of those with documented haemoglobin measurements were anaemic, 
could suggest that these measurements were taken in those suspected of having anaemia. 
Data were also unavailable for patient height and thus we were unable to calculate body 
mass index (BMI). Whilst it may have been ideal to determine actual patient outcomes of all 
patients, we could not trace and establish true patient outcomes in those patients who were 
classified as LTFU and there is a possibility that some may have been alive or dead and thus 
misclassified. This potential misclassification of ART patients in the attrition group is not 
uncommon in retrospective reviews of other ART patient cohorts in other resource-limited 
settings.
In conclusion, our study findings show that males present late for ART when compared with 
their female counterparts. This may partly explain their poorer outcomes in comparison to 
females. This observation highlights the need for strategies tailored to males in order to 
encourage early HIV testing and enrolment into HIV treatment and care.
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